Investment Rating - The report maintains an "Outperform" rating for Sichuan Kelun-Biotech [2][9]. Core Insights - The company achieved a revenue of CNY 2.06 billion in FY25, reflecting a year-on-year growth of 6.5%. Drug sales revenue was CNY 540 million, while licensing and collaboration income decreased by 20% to CNY 1.50 billion. The net loss for the year was CNY 380 million, compared to a loss of CNY 270 million in FY24 [3][16]. - Several products have been successfully commercialized in China, including sac-TMT, tagitanlimab, cetuximab N01, and trastuzumab botidotin, with the first three included in the National Reimbursement Drug List (NRDL) [4][17]. - The company is progressing with multiple clinical trials, including 17 global Phase 3 trials for sac-TMT, with data readouts expected to begin in 2027 [5][19]. Financial Summary - Revenue projections for FY26 and FY27 have been adjusted to CNY 2.8 billion and CNY 4.8 billion, respectively, reflecting the company's commercialization progress and potential changes in milestone payments [9][21]. - The gross profit margin is expected to improve from 71.9% in FY25 to 77.5% in FY27, indicating enhanced profitability as the company scales its operations [14][21]. - The net profit attributable to the parent is forecasted to be CNY -220 million in FY26 and CNY 820 million in FY27, showing a significant turnaround in profitability [9][21].

Investment Rating - The report maintains an "Outperform" rating for the company [2][9]. Core Insights - The company achieved a revenue of CNY 2.06 billion in FY25, reflecting a year-on-year growth of 6.5%. Drug sales revenue was CNY 540 million, while licensing and collaboration income decreased by 20% to CNY 1.50 billion. The net loss for the year was CNY 380 million, compared to a loss of CNY 270 million in FY24 [3][16]. - Several products have been successfully commercialized in China, including sac-TMT, tagitanlimab, cetuximab N01, and trastuzumab botidotin, with the first three included in the National Reimbursement Drug List (NRDL). The NDA for lenvatinib fumarate has been submitted, with commercialization expected to start in 2027 [4][17]. - The company is progressing well in its clinical trials, with sac-TMT approved for multiple indications in China and 17 global Phase 3 trials initiated by Merck. Key data readouts are anticipated in 2026 and 2027 [5][19][23]. Financial Summary - Revenue projections for FY26 and FY27 have been adjusted to CNY 2.8 billion and CNY 4.8 billion, respectively, reflecting the company's commercialization progress. The net profit attributable to the parent is forecasted to be CNY -220 million in FY26 and CNY 820 million in FY27 [9][21]. - The gross profit margin is expected to improve from 71.9% in FY25 to 77.5% in FY27, indicating enhanced operational efficiency [14].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's core product, sac-TMT (Lukangshatuo monoclonal antibody), is showing strong commercialization progress, contributing significantly to sales revenue [6][7] - The company has adjusted its revenue forecasts for 2025 to 2027, expecting revenues of 17.53 billion, 28.67 billion, and 48.64 billion respectively, reflecting a positive outlook on sales growth [6] - The company is preparing for multiple data disclosures at the ESMO conference in 2025, which could serve as potential catalysts for growth [8] Financial Performance Summary - In H1 2025, the company reported revenue of 950 million, a year-on-year decrease of 31.3%, primarily due to high milestone payments recognized in the same period of 2024 [6] - The net loss attributable to the parent company was 145 million, with an adjusted net loss of 69 million [6] - The sales revenue from pharmaceuticals reached 309.8 million, with sac-TMT accounting for 97.6% of total pharmaceutical sales [7] Revenue and Profit Forecasts - The company expects a revenue decline of 9.3% in 2025, followed by significant growth of 63.5% in 2026 and 69.7% in 2027 [9] - The projected net profit for 2027 is expected to reach 1,049 million, indicating a turnaround from losses in previous years [9] Valuation Metrics - The price-to-sales (P/S) ratios for 2025, 2026, and 2027 are projected to be 56.7, 34.6, and 20.4 respectively [9] - The price-to-book (P/B) ratios for the same years are expected to be 37.3, 40.7, and 28.3 [9]